Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
This article reviews the evolution of antihypertensive therapy and highlights the need to reexamine previously held beliefs regarding its long-term benefits and risks.
Hypertension is a major public health problem, afflicting at least 35 million people in the United States. Impressive advances in the pharmacotherapy of hypertension have been made over the past three decades. More than 10 million hypertensive patients are currently receiving antihypertensive medications,1 at an estimated cost of approximately $2.5 billion — figures that exceed those for any other single disease.However, important questions remain regarding the long-term benefits and risks of therapy.Several developments in the past few years have led to a reexamination of previously held beliefs about the management of hypertension. The results of several large clinical . . .
No takes yet. Share an insight, caveat, or question.
Aram V. Chobanian (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: